Title |
Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells
|
---|---|
Published in |
Molecular Pharmaceutics, November 2015
|
DOI | 10.1021/acs.molpharmaceut.5b00694 |
Pubmed ID | |
Authors |
Jeyarama S. Ananta, Ramasamy Paulmurugan, Tarik F. Massoud |
Abstract |
Glioblastoma (GBM) generally exhibits high IC50 values for its standard drug treatment, temozolomide (TMZ). MicroRNA-21 (miR-21) is an oncomiR overexpressed in GBM, thus controlling important aspects of glioma biology. We hypothesized that PLGA nanoparticles carrying antisense miR-21 to glioblastoma cells might beneficially knock down endogenous miR-21 prior to TMZ treatment. PLGA nanoparticles encapsulating antisense miR-21 were effective in intracellular delivery and sustained silencing (p < 0.01) of miR-21 function in U87 MG, LN229, and T98G cells. Prior antisense miR-21 delivery significantly reduced the number of viable cells (p < 0.001), and increased (1.6-fold) cell cycle arrest at G2/M phase upon TMZ treatment in U87 MG cells. There was overexpression of the miR-21 target genes PTEN (by 67%) and caspase-3 (by 15%) upon cotreatment. This promising PLGA nanoparticle-based platform for antisense miR-21 delivery to GBM is an effective cotherapeutic strategy in cell culture, warranting the need for further studies prior to future clinical translation. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Portugal | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 60 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 19 | 32% |
Researcher | 9 | 15% |
Student > Master | 6 | 10% |
Student > Bachelor | 3 | 5% |
Lecturer | 2 | 3% |
Other | 6 | 10% |
Unknown | 15 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 18 | 30% |
Medicine and Dentistry | 8 | 13% |
Chemistry | 4 | 7% |
Agricultural and Biological Sciences | 4 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
Other | 8 | 13% |
Unknown | 15 | 25% |